Retatrutide
€299.00
Productinformation
3ml cartridge with 10mg tirzepatide
Expiration date: 01-11-2027
Pen delivers doses of 0.5, 1, 1.5, 2 or 2.5mg.
3ml cartridge with 40mg tirzepatide
Expiration date: 01-12-2027
Pen delivers 4x10mg.
1mg 6 clicks, 2mg 12 clicks, 5mg 30 clicks, 10mg 60 clicks.
Keep in the fridge between 3 and 7 °C.
Use only 8 weeks after first dose.
Dosing Schedule
Start: 1-2 mg per week
Then: increase step by step.
Possible doses are: 1 – 2 – 4 – 8 – 12 mg per week
Maximum dose: 12 mg per week
“The goal is to find the right balance between minimizing side effects and achieving sufficient appetite suppression. So the dose can be lower than suggested”
Retatrutide is an investigational treatment for obesity and metabolic disease, designed as a triple-agonist that activates the GLP-1, GIP, and glucagon receptors. By engaging all three pathways, it enhances insulin secretion, suppresses appetite, slows gastric emptying, and also increases energy expenditure—combining the effects of multiple hormonal signals to reduce calorie intake and boost calorie burn.
In a phase 2 trial over 48 weeks involving adults with obesity, retatrutide delivered mean weight losses of −8.7% at 1 mg, −17.1% at 4 mg, −22.8% at 8 mg, and −24.2% at 12 mg, compared to −2.1% with placebo. At higher doses, nearly all participants lost at least 5% of baseline weight, and many achieved 15–25% reductions.
Beyond weight loss, retatrutide improved cardiometabolic health, reducing waist circumference, lowering blood pressure, improving lipids, glucose, insulin sensitivity, and liver fat markers. The most common side effects were gastrointestinal, generally mild to moderate.
The pen comes with a clear instruction flyer. According to our customers, this makes the pen easy to use.
Weight Loss Pen Europe GmbH
Biocampus München
82152 Martinsried
Germany